Tarsus reports FY2022 net loss of $62.1M; PDUFA for TP-03 on Aug 25, 2023

Tarsus Pharmaceuticals, Inc.

Full-year net loss $62.1M vs $13.8M in 2021; revenue from TP-03 out-license was $25.8M.
Cash, cash equivalents and marketable securities $217.0M; runway into at least 2H 2026.
TP-03 NDA accepted; PDUFA target action date August 25, 2023 for Demodex blepharitis.
Completed enrollment of Ersa Phase 2a (MGD); topline data expected H2 2023.
Initiated Galatea Phase 2a trial of TP-04 for rosacea; Phase 1 safety supported progression.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tarsus Pharmaceuticals, Inc. reported the full-year ended December 31, 2022 results: revenue $25.8 million.

Period: the full-year ended December 31, 2022
Revenue: $25.8 million
Result: reported results

Exact text from the filing

blepharitis ● TP-03 Topline Phase 2a (Ersa) Meibomian Gland Disease ● Full-Year 2022 Financial Results • Full year TP-03 out-license revenue for greater China territory was $25.8 million, compared to $57.0 million in 2021 • Full year net loss was $62.1 million, compared to $13.8 million in 2021 • Full year research and development expenses were $42.6 million,

View on SEC.gov

Browse all earnings releases →

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.